Vaccine · 2026
RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Peng-Jun, Hung Mei-Chuan, Srivastav Anup, Kriss Jennifer L, Black Carla L, Zhou Tianyi, Schorpp Susanne, Singleton James A
Аннотация
BACKGROUND: Older adults are more likely to develop severe respiratory syncytial virus (RSV) disease and need hospitalization. In 2024, RSV vaccination was recommended in the United States by ACIP. for adults aged 60-74 years at increased risk of severe RSV and all adults aged ≥75 years.
METHODS: Data from the National Immunization Survey-Adult COVID Module collected during September 2024-April 2025 were analyzed to assess RSV vaccination coverage at national and state level using the Kaplan-Meier survival analysis procedure. Multivariable logistic regression analysis and predictive marginals were conducted to assess factors associated with RSV vaccination.
RESULTS: RSV vaccination coverage by the end of the 2024-25 season among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years was 38.3% and 41.5%, respectively, and of those who had ever received RSV vaccination, 56.2% and 55.4%, respectively, reported receiving it before start of the 2024-25 season. Coverage ranged from 10.8% in Virgin Islands to 61.2% in Michigan among adults aged 60-74 years at increased risk, and 7.2% in Virgin Islands to 57.6% in Colorado among adults aged ≥75 years. Characteristics independently associated with increased RSV vaccination among both adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years included household income above the poverty level, having college graduate or higher education, not having a disability, and receiving provider recommendation for RSV vaccination.
CONCLUSIONS: By the end of the 2024-25 season, RSV vaccination coverage among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years remains low in the United States. Wide variation in coverage across states/territories were observed. Differences by demographic and other factors were observed in vaccination uptake. Healthcare providers can educate and encourage adults to receive vaccine when they are eligible.
METHODS: Data from the National Immunization Survey-Adult COVID Module collected during September 2024-April 2025 were analyzed to assess RSV vaccination coverage at national and state level using the Kaplan-Meier survival analysis procedure. Multivariable logistic regression analysis and predictive marginals were conducted to assess factors associated with RSV vaccination.
RESULTS: RSV vaccination coverage by the end of the 2024-25 season among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years was 38.3% and 41.5%, respectively, and of those who had ever received RSV vaccination, 56.2% and 55.4%, respectively, reported receiving it before start of the 2024-25 season. Coverage ranged from 10.8% in Virgin Islands to 61.2% in Michigan among adults aged 60-74 years at increased risk, and 7.2% in Virgin Islands to 57.6% in Colorado among adults aged ≥75 years. Characteristics independently associated with increased RSV vaccination among both adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years included household income above the poverty level, having college graduate or higher education, not having a disability, and receiving provider recommendation for RSV vaccination.
CONCLUSIONS: By the end of the 2024-25 season, RSV vaccination coverage among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years remains low in the United States. Wide variation in coverage across states/territories were observed. Differences by demographic and other factors were observed in vaccination uptake. Healthcare providers can educate and encourage adults to receive vaccine when they are eligible.